Bortezomib (PS-341)

製品コードS1013 別名：LDP-341, MLM341

分子量(MW)：384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ

価格(税別)

5mg	JPY 13600
25mg	JPY 46800
100mg	JPY 113200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

具体的な在庫状況を確認してください。代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(250)

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

ターゲット

20S proteasome ^[1]
(Cell-free assay)

0.6 nM(Ki)

体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF-7	NEjMUGNEgXSxdH;4bYMhSXO\|YYm=	MVO1NEDPxE1?	MVu0PEBp	NIj3fpZFVVOR	NFvRPW1McWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm	MnG2NVA1QTl4NEO=
OVCA 429	NIfx[YdHfW6ldHnvckBCe3OjeR?=	MYGzNFAhdk1?	M1zJUFQ5KGh?	MWTEUXNQ	MkLzSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz	MkfWNVA6QTl5Nk[=
RPMI8226	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rMdFExOCCwTR?=	NECweJg1QCCq	MYLEUXNQ	M4HyXmlEPTB;M{Cgcm0>	MoDMNVE{ODZ2OEm=
Dox40	NUPiSZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LKRVExOCCwTR?=	MXO0PEBp	MoLkSG1UVw>?	M4Sxb2lEPTB;NECgcm0>	NGXtW3MyOTNyNkS4PS=>
MR20	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNFAhdk1?	NUj3N5l7PDhiaB?=	NUPMOIdkTE2VTx?=	NFvuZ5ZKSzVyPUKwJI5O	NYLxdpVROTF\|ME[0PFk>
LR5	NGPmfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLaV41qOTByIH7N	MlzzOFghcA>?	M{\WTGROW09?	MlfyTWM2OD1{MDDuUS=>	NXHsdVI5OTF\|ME[0PFk>
U266	NVfMe3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonENVAxKG6P	NF;nZ\|A1QCCq	NYrXbYdUTE2VTx?=	MVHJR\|UxRTNibl2=	NF3RSlcyOTNyNkS4PS=>
IM-9	M3LaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\RN3YyODBibl2=	NFXEXpI1QCCq	NHjFbJlFVVOR	NHrObnRKSzVyPU[gcm0>	Mn\3NVE{ODZ2OEm=
Hs Sultan	NEeyeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[xNFAhdk1?	NFH0WmU1QCCq	NVX3N2g3TE2VTx?=	MlPnTWM2OD1{MDDuUS=>	NGPUd3cyOTNyNkS4PS=>
PAM-LY2	M2mxRWZ2dmO2aX;uJGF{e2G7	MoX0NVAxKG6P	NIT1PWoyOiCq	M1vGdmROW09?	MVjJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?=	NXSy[FcxOTF\|NUC5NVM>
PAM 212	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nEPVExOCCwTR?=	NXzjc\|FqPzJiaB?=	NXzxV5M2TE2VTx?=	NVrObJBWUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	M13rTlEyOzVyOUGz
PAM-LY2	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\IfVExOCCwTR?=	NWXsNFVCPzJiaB?=	MmTxSG1UVw>?	NFrp[XVKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NH7EUpQyOTN3MEmxNy=>
B4B8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEToOGEyODBibl2=	NGm3Zow4OiCq	NYLqRnFGTE2VTx?=	MWfJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MoXHNVE{PTB7MUO=
B7E3	M3q1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXixNFAhdk1?	NH:0eWI4OiCq	MVXEUXNQ	NW\EUWkyUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MkfCNVE{PTB7MUO=
UM-SCC-9	NGPaT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPoWph7OTByIH7N	NYqwOJFtPzJiaB?=	NH7Jcm1FVVOR	NF\iOndKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NYnLepNMOTF\|NUC5NVM>
UM-SCC-11B	M3LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDzNVAxKG6P	MX23NkBp	NFzlZnhFVVOR	NHfYO2pKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MljHNVE{PTB7MUO=
H460	NF3COVNHfW6ldHnvckBCe3OjeR?=	NGrFdlMyOCEQvF2=	NE\aZmMzPCCq	MX3EUXNQ	NWfBT\|hyUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW\|dB?=	M2f6dFEzPDl{MUG3
U266	NUPnTIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi4dWREPTByIH7nM41t	NGTrNYQ1QCCq	MkXQSG1UVw>?	NGXVWFFKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NHnY[2YyOjZ\|MU[xPS=>
ARH77	NXKz[2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:4O3E2ODBibnevcYw>	M375SVQ5KGh?	MUjEUXNQ	NFfB[YZKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MWixNlY{OTZzOR?=
WAD-1	NIDu[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVK1NFAhdmdxbXy=	M1;v[\|Q5KGh?	MX3EUXNQ	NVvKSoc5UW6qaXLpeJMh[2WubDDndo94fGh?	Ml7JNVI3OzF4MUm=
U266/LR7	NVT3bVU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nyc\|UxOCCwZz;tcC=>	M160clQ5KGh?	NUXCSW1ETE2VTx?=	MnvyTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	M{\WfVEzPjNzNkG5
U266/dox4	M1\sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzkbmg2ODBibnevcYw>	NWThZ2lnPDhiaB?=	NHnCcGFFVVOR	NYHRUYdYUW6qaXLpeJMh[2WubDDndo94fGh?	MlztNVI3OzF4MUm=
RPMI8226/LR5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjzZmFRPTByIH7nM41t	MoXLOFghcA>?	MWXEUXNQ	MVXJcohq[mm2czDj[YxtKGe{b4f0bC=>	NEnIUmYyOjZ\|MU[xPS=>
H460	NG\yc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHpNVAh\|ryP	MorMO\|IhcA>?	M1;qeGROW09?	M2jNUmlEPTB;MUCwJI5O	NYH2PIdOOTJ4M{G2NlA>
H358	NIfQVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvnZoMyOCEQvF2=	M{fFXFczKGh?	NWPkUJo{TE2VTx?=	NUTHfYo4UUN3ME23NEBvVQ>?	NHu3ZocyOjZ\|MU[yNC=>
H322	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV61TY9YOTBizszN	MkK2O\|IhcA>?	MXjEUXNQ	MlfITWM2OD14MkCgcm0>	NF7xNW8yOjZ\|MU[yNC=>
H460	Mn;mSpVv[3Srb36gRZN{[Xl?	NGTvSlYyODBibl2=	M2\NW\|I1KGh?	NGnybGtFVVOR	M1[5cWlv\HWlZYOgS\|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO\|ZX3icJku\Gm\|YYPz[Y1jdHl?	M4DlNVEzPjNzNkKw
LNCap-Pro5	M3O4[GZ2dmO2aX;uJGF{e2G7	MUCxJO69VQ>?	NVT4WYNDPCCq	MoD1SG1UVw>?	MmTDV5Ri[mmuaYrld{BxPTN?	NETBeHkyPDZzMkWzNi=>
T29	NH7NVHBCeG:ydH;zbZMhSXO\|YYm=	M2nnS\|UxKG6P	MXO0PEBpKA>?	MmDZSG1UVw>?	MXTJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M{TzO\|E3Pzd6MUe5
T29Kt1	NFzwUFRCeG:ydH;zbZMhSXO\|YYm=	MmnQOVAhdk1?	MnfqOFghcCB?	M3L0bmROW09?	NXjzZpI2UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NX\weotCOTZ5N{ixO\|k>
HCT116	NHGybIhCeG:ydH;zbZMhSXO\|YYm=	NULVbJQ{PTBibl2=	Ml;UOFghcCB?	NGPmeoNFVVOR	NFjDRYVKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M{\ueVE3Pzd6MUe5
HKe-3	MkX1RZBweHSxc3nzJGF{e2G7	MV61NEBvVQ>?	M3fpN\|Q5KGhi	M3rHe2ROW09?	NVnxOGpCUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NUjYfI5WOTZ5N{ixO\|k>
NB-1691	NUKzdI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPiRYNWOSEQvF2=	M2DReFczKGh?		NGjRRVJKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW=	M4\6NlE4Pjh7Nki0
CHLA-255	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxJO69VQ>?	MoPoO\|IhcA>?		M1z5N2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?=	M1n1OVE4Pjh7Nki0
SK-N-AS	NF3XOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mln6NUDPxE1?	NIK3THU4OiCq		NWLzfo9uUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=>	MVyxO\|Y5QTZ6NB?=
NB-1691	NXrxU5hoTnWwY4Tpc44hSXO\|YYm=	Mlr5NVAhdk1?	M3myNlI1KGh?		MnHsV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=>	MmrxNVc3QDl4OES=
CHLA-255	NHjacZlHfW6ldHnvckBCe3OjeR?=	MXWxNEBvVQ>?	NH7NSGwzPCCq		MoPIUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V?	MU[xO\|Y5QTZ6NB?=
RPMI 8226	NW\I[5dRTnWwY4Tpc44hSXO\|YYm=	M2DqXlIxKG6P	Mlv3PEBp		M4nzNnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NHT2[ngyQTR\|NkC1NC=>
MM.1S	NVjz[nJwTnWwY4Tpc44hSXO\|YYm=	MYiyNEBvVQ>?	MYC4JIg>		MnG3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MYKxPVQ{PjB3MB?=
U266	NWnhTFVwTnWwY4Tpc44hSXO\|YYm=	MWKyNEBvVQ>?	Mk\1PEBp		MX3TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	MVSxPVQ{PjB3MB?=
OPM1	NVT5WnFKTnWwY4Tpc44hSXO\|YYm=	MnLkNlAhdk1?	NGLxVm85KGh?		M3jSN3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	M2nV[VE6PDN4MEWw
INA6	NGOyVphHfW6ldHnvckBCe3OjeR?=	Mo\vNlAhdk1?	NH;Pb4Y5KGh?		NILJZodUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	NIPmWnoyQTR\|NkC1NC=>
OPM2	NETYdW9HfW6ldHnvckBCe3OjeR?=	MlHVNlAhdk1?	NYfGcJN2QCCq		MWXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	M3vESVE6PDN4MEWw
RPMI 8226	M4\HVWZ2dmO2aX;uJGF{e2G7	NXPCRVBsOjBibl2=	M4jqUVghcA>?		NHHs[FNKdmS3Y3XzJGRPSSC\|eX70bIV{cXN?	MoDuNVk1OzZyNUC=
BaF/3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlqwNVAxKG6P	NX;RSmhuPDhiaB?=		MUTJR\|UxRTZwMjDuUS=>	NGHsZ4gzODNyNU[5Ni=>
BaF/3-p210	NGjPNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofxNVAxKG6P	MmryOFghcA>?		NH;qXI9KSzVyPUSuO{BvVQ>?	NWSz[2dXOjB\|MEW2PVI>
TCC-S	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\mSVExOCCwTR?=	NFu2cZk1QCCq		M3:4SGlEPTB;Mj64JI5O	MV2yNFMxPTZ7Mh?=
BaF/3	M37nRmZ2dmO2aX;uJGF{e2G7	MY[2JI5O	NFn3bYc1QCCq		NFS3coFKdmS3Y3XzJIEh\3KnYYSgS\|Eh[2WubD3jfYNt\SCjcoLld5Q>	NVe1XYg2OjB\|MEW2PVI>
BaF/3-p210	NUjWW\|B1TnWwY4Tpc44hSXO\|YYm=	NH\PXpE3KG6P	M3nNclQ5KGh?		M2\XPWlv\HWlZYOgZUB{dGmpaISgS\|Eh[2WubD3jfYNt\SCjcoLld5Q>	Mn7hNlA{ODV4OUK=
BaF/3-p210	NWD2SWU{TnWwY4Tpc44hSXO\|YYm=	MkDMOkBvVQ>?	MUCyOEBp		M3jBenJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk	MoH5NlA{ODV4OUK=
Raji	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ew[FEh\|ryP	NY[3TGYzOjRiaB?=		M3;ZS3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M3\HT\|IyOTdyOUi4
LCL-1	NUPLRVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPDfZlCOSEQvF2=	MWSyOEBp		M{LMW3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	Mnf2NlEyPzB7OEi=
LCL-2	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTnNUDPxE1?	M1jy[\|I1KGh?		NVvae4RLWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NXfheJNyOjFzN{C5PFg>
BJAB	M2\CVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7qZZYyKM7:TR?=	NVzxdFdDOjRiaB?=		NVHtclZoWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NUHMVZp[OjFzN{C5PFg>
SNT-13	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXHO4EyKM7:TR?=	MVKyOEBp		MoXXVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	NIm1SXEzOTF5MEm4PC=>
SNT-16	NX7ESVVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\GU4UyKM7:TR?=	M3TZblI1KGh?		NWDve\|FtWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	MWKyNVE4ODl6OB?=
Jurkat	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LnNVEh\|ryP	NV:zfYNKOjRiaB?=		M1q0OnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M2DoT\|IyOTdyOUi4
KAI-3	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPEeJUyKM7:TR?=	M2jSW\|I1KGh?		NHf0N\|ZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NEnhXoMzOTF5MEm4PC=>
SNK-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHThVIEyKM7:TR?=	NVuyWok5OjRiaB?=		MmnwVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	Mk\RNlEyPzB7OEi=
KHYG-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HQRVEh\|ryP	NYPK[2ZwOjRiaB?=		NUf0XVNYWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NIq3NlMzOTF5MEm4PC=>
SNT-16	NEPkd\|RCeG:ydH;zbZMhSXO\|YYm=	NE\yW3UyKM7:TR?=	MmXWOkBp		M3rGNGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NX;Te\|N1OjFzN{C5PFg>
Jurkat	NUX1SJQxSXCxcITvd4l{KEG\|c3H5	M2eyOVEh\|ryP	M4jLSFYhcA>?		MUTJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MVuyNVE4ODl6OB?=
KAI-3	MVvBdI9xfG:\|aYOgRZN{[Xl?	MWmxJO69VQ>?	NH3vWlE3KGh?		MXXJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	Mk\WNlEyPzB7OEi=
KHYG-1	M3XVOWFxd3C2b4Ppd{BCe3OjeR?=	MoTzNUDPxE1?	MoezOkBp		M1fTc2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NF\JeVczOTF5MEm4PC=>
SNT-13	M3;MO2FvfGm4aYLhcEBCe3OjeR?=	NX:0R4NFOSEQvF2=	NFK1d40zPCCq		MoLpTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX	MofQNlEyPzB7OEi=
SNT-16	M1nMSGFvfGm4aYLhcEBCe3OjeR?=	NX74PWF[OSEQvF2=	NFPTPYIzPCCq		NHS3NIlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	NGLKW4czOTF5MEm4PC=>
KAI-3	NWLQVYVESW62aY\pdoFtKEG\|c3H5	MlzZNUDPxE1?	MU[yOEBp		NF23Ro9KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	NFX5S3AzOTF5MEm4PC=>
SNK-6	MXjBcpRqfmm{YXygRZN{[Xl?	M{PyNVEh\|ryP	M1TOZVI1KGh?		MWTJcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	NIXSfZczOTF5MEm4PC=>
RAW 264.7	M{D5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLlNVAxKG6P	NFjFVZA1QCCq		M{XDS3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MXeyNlQzPzF3NB?=
A375	MkSxRZBweHSxc3nzJGF{e2G7	Ml\SNVAhdk1?	M4f2UlI1KGh?		NXjNRXJsUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NHjOfVEzOzB5OUC4Ny=>
BLM	M4PDUmFxd3C2b4Ppd{BCe3OjeR?=	NYfrd3hYOTBibl2=	NUP1elNrOjRiaB?=		M1S2dmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MljpNlMxPzlyOEO=
A375	M3zXSmF2fG:yaHHnfUBCe3OjeR?=	M33n[VExKG6P	M{THPVEzKGh?		NX;ERlhqUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>	MXuyN\|A4QTB6Mx?=
BLM	MX\BeZRweGijZ4mgRZN{[Xl?	M3\tc\|ExKG6P	MXuxNkBp		Mo[yTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	MofqNlMxPzlyOEO=
H1299	M13zc2Fxd3C2b4Ppd{BCe3OjeR?=	MnS1PFAhdk1?	MX[yOEBp	MXfEUXNQ	NGLtfIZU\W6\|aYTpfoV{KE6VQ1zDJINmdGy\|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?=	NHPDSoozPTN{M{[5Ny=>
Hut-78	MnHlSpVv[3Srb36gRZN{[Xl?	M16xelExOCCwTR?=	MXmyOEBp	NF62ZXpFVVOR	Mor3SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w	MlLKNlU3QDF\|M{W=
H9	NYC3UIxnTnWwY4Tpc44hSXO\|YYm=	MoXnNVAxKG6P	MVOyOEBp	M4fq[2ROW09?	NWXRT2tOTG:5boLl[5Vt[XSnczDUS2Yu\|rJzIHHu[EBKVC1zMTDlfJBz\XO\|aX;u	NIrWdo8zPTZ6MUOzOS=>
HH	NGD4OllHfW6ldHnvckBCe3OjeR?=	M1TUUFExOCCwTR?=	M1T2[FI1KGh?	NEXvPItFVVOR	NVvCOYk4\G:5boLl[5Vt[XSnczDUS2Yu\|rJzIHHu[EBKVC1zMjDlfJBz\XO\|aX;u	M4LD[lI2PjhzM{O1
Hut-78	MYjNbYdz[XSrb36gRZN{[Xl?	M4fibVExOCCwTR?=	NEXidZUzPCCq	MYDEUXNQ	MVzS[YR2[2W\|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn	MWOyOVY5OTN\|NR?=
HH	M4KzbW1q\3KjdHnvckBCe3OjeR?=	M1rlRlExOCCwTR?=	MlKzNlQhcA>?	NF7EdJRFVVOR	NH7uRpRT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl	NX3RVZFFOjV4OEGzN\|U>
U937	NXXISpRtTnWwY4Tpc44hSXO\|YYm=	M1L5V\|ExOCCwTR?=	NXrneoN3PiCq		MnnkTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>?	NIrISJczPTd7MUS3Oy=>
human PBMC	NGD3fHNHfW6ldHnvckBCe3OjeR?=	NEHpXlQyODBibl2=	NFq2TGQzPCCq		NVH1R4pPUW6mdXPld{BKVC16IILlcIVie2V?	Mm\6NlU4QTF2N{e=
ES6	M{PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXrdWdKSzVyPUCuNFAzOSCwTR?=	MkjUV2FPT0WU
SK-UT-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHwTWM2OD1yLkG2N{BvVQ>?	NUjUR4twW0GQR1XS
SH-4	M2HsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\STWM2OD1yLkG3N{BvVQ>?	NXL1N3YyW0GQR1XS
TE-9	NF7tdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HUWmlEPTB;MD6xPFIhdk1?	NGT3XHJUSU6JRWK=
A253	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULqb3NHUUN3ME2wMlIxQCCwTR?=	MnSyV2FPT0WU
no-10	NUHod4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S5V2lEPTB;MD6yNUBvVQ>?	NUf2WlBtW0GQR1XS
MMAC-SF	NFTjXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonGTWM2OD1yLkKxOkBvVQ>?	M2fTUnNCVkeHUh?=
A101D	NY\5cXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwMkK1JI5O	NEDrV4pUSU6JRWK=
NTERA-S-cl-D1	NWnFfFExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYr5R4x5UUN3ME2wMlI1OyCwTR?=	NHyzepdUSU6JRWK=
8-MG-BA	M13Xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPWTWM2OD1yLkK1JI5O	NX;qW3lKW0GQR1XS
KNS-42	NVWyN5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfvTWM2OD1yLkK1PEBvVQ>?	NVTGOINrW0GQR1XS
LXF-289	NVnCOmZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMk[5JI5O	NYHabZJIW0GQR1XS
OVCAR-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrScFNKSzVyPUCuNlg6KG6P	NFL6[\|NUSU6JRWK=
LOUCY	M3zXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzZcW13UUN3ME2wMlI6OyCwTR?=	MkfJV2FPT0WU
BB65-RCC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnz4TWM2OD1yLkOwOEBvVQ>?	NYnufJFXW0GQR1XS
D-542MG	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPi[ndpUUN3ME2wMlMzQSCwTR?=	NF70R5BUSU6JRWK=
ONS-76	M{jQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorzTWM2OD1yLkOzJI5O	M1f4XHNCVkeHUh?=
BB30-HNC	NV;COotjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LjV2lEPTB;MD6zN\|Uhdk1?	NHzIPGhUSU6JRWK=
KS-1	Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrUTWM2OD1yLkO0JI5O	NWfhW4QxW0GQR1XS
A388	M3jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwM{W2JI5O	NX\hWFN4W0GQR1XS
ES8	NGTPcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17GVGlEPTB;MD60JI5O	NV;jUJNwW0GQR1XS
MZ2-MEL	NIWzcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnzR2NKSzVyPUCuOFA4KG6P	MVTTRW5ITVJ?
HCC2998	M4Ht[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjJVVRTUUN3ME2wMlQyOiCwTR?=	NWPqUGFiW0GQR1XS
D-247MG	NI\wUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4[1cGlEPTB;MD60NVMhdk1?	MlTQV2FPT0WU
ACN	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D1SWlEPTB;MD60NVchdk1?	M3nhVHNCVkeHUh?=
LB2518-MEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2exNmlEPTB;MD60NlUhdk1?	NEfHWnhUSU6JRWK=
ES1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjsTWM2OD1yLkSzJI5O	MnLyV2FPT0WU
HCE-T	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn0VmRKSzVyPUCuOFM6KG6P	MYTTRW5ITVJ?
OS-RC-2	NIjMcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHHc4pKSzVyPUCuOFQhdk1?	NULvOIlqW0GQR1XS
MFH-ino	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle2TWM2OD1yLkS0N{BvVQ>?	NFXtfm9USU6JRWK=
OCUB-M	Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPIXYxKSzVyPUCuOFQ4KG6P	M1z5N3NCVkeHUh?=
CP66-MEL	NIizNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTBwNEezJI5O	NW\2eYl{W0GQR1XS
LB771-HNC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnyyTWM2OD1yLkS3OEBvVQ>?	M2DBUnNCVkeHUh?=
DSH1	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv5XXFKSzVyPUCuOFghdk1?	NV2wcmw2W0GQR1XS
HUTU-80	NGqxVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\kfYpKSzVyPUCuOVM{KG6P	MnP1V2FPT0WU
CESS	M4\sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzYcI9sUUN3ME2wMlU{QCCwTR?=	NFHq[ZRUSU6JRWK=
NCI-H747	NF3yb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HFemlEPTB;MD61N\|khdk1?	NXHu[\|BNW0GQR1XS
HT-144	M4n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwNUe2JI5O	NIe5SpFUSU6JRWK=
COLO-829	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvpcmFKSzVyPUCuOlE1KG6P	M{G0[nNCVkeHUh?=
A4-Fuk	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLTVHM5UUN3ME2wMlYzOyCwTR?=	NXfJd3Q4W0GQR1XS
GI-ME-N	M{WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnwTWM2OD1yLk[zOEBvVQ>?	MoXSV2FPT0WU
LB831-BLC	NWTYdppVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwNkSxJI5O	MVvTRW5ITVJ?
HOP-62	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TwVWlEPTB;MD62OFchdk1?	M2f4SnNCVkeHUh?=
BB49-HNC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Gw[2lEPTB;MD62OVIhdk1?	NXP4cVhMW0GQR1XS
D-336MG	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTBwNkW3JI5O	NEnvbpVUSU6JRWK=
TK10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwNke5JI5O	NGXCSoRUSU6JRWK=
Ramos-2G6-4C10	NULMV2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwNkmzJI5O	M3vXbXNCVkeHUh?=
LB373-MEL-D	NX\6dXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlW5TWM2OD1yLkegcm0>	M{nw[XNCVkeHUh?=
SF126	NVLJNlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPNdHFKSzVyPUCuO\|AyKG6P	Ml;QV2FPT0WU
UACC-257	NFHXVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwN{Ggcm0>	NGDwN5RUSU6JRWK=
KINGS-1	M{HXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mne1TWM2OD1yLkeyNkBvVQ>?	NYjwOHN3W0GQR1XS
LS-513	NHrCd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzRTHhTUUN3ME2wMlc{QSCwTR?=	MlvsV2FPT0WU
GI-1	NHLCW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzETWM2OD1yLke2OEBvVQ>?	NYDpXGM{W0GQR1XS
ES7	M4HhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnDVndKUUN3ME2wMlc3PiCwTR?=	NYDBcXhvW0GQR1XS
LB2241-RCC	M33nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3FTWM2OD1yLkiwOEBvVQ>?	NX;nTpprW0GQR1XS
D-263MG	NI\Yc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvPfIFKSzVyPUCuPFA4KG6P	MlXMV2FPT0WU
SW684	MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XjN2lEPTB;MD64NlEhdk1?	NVT4d3VmW0GQR1XS
ML-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnrUHBKSzVyPUCuPFIyKG6P	NGTUW4hUSU6JRWK=
SK-LMS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrnUHJKSzVyPUCuPFU1KG6P	MYrTRW5ITVJ?
TE-5	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwOE[1JI5O	MYfTRW5ITVJ?
QIMR-WIL	NWjWRYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nlNGlEPTB;MD64PFkhdk1?	Ml2zV2FPT0WU
NCI-H1355	NFzvZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjEcow{UUN3ME2wMlg6PSCwTR?=	NHnDboZUSU6JRWK=
SNB75	NXq4dGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jGWmlEPTB;MD65NVIhdk1?	NHfiVHVUSU6JRWK=
RXF393	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;2VWlEPTB;MD65NVQhdk1?	MWPTRW5ITVJ?
IST-MEL1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PN[2lEPTB;MD65NVchdk1?	NWn4c5pRW0GQR1XS
SF268	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzXUpBuUUN3ME2wMlkzOyCwTR?=	NXvucHlIW0GQR1XS
KALS-1	NYO4foxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonQTWM2OD1yLkmyOUBvVQ>?	NHXmZm9USU6JRWK=
HC-1	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPvTWM2OD1yLkm3OUBvVQ>?	NIPyb4pUSU6JRWK=
SW872	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK4V5FKSzVyPUCuPVk3KG6P	NHrlc2hUSU6JRWK=
PSN1	M13jS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFwMEGgcm0>	NFHtfYVUSU6JRWK=
TE-1	NXvYfINDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFwMEOgcm0>	MnXvV2FPT0WU
TE-10	NEjoWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVy2PFJzUUN3ME2xMlA{KG6P	MlzqV2FPT0WU
RKO	NIfR[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIq5dG1KSzVyPUGuNFYhdk1?	MoriV2FPT0WU
LC-2-ad	NGfjRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[3RXFKSzVyPUGuNFghdk1?	NX7ScVY2W0GQR1XS
SK-MM-2	NEnkeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rYT2lEPTB;MT6wPUBvVQ>?	M2PYTXNCVkeHUh?=
VA-ES-BJ	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NESyOWNKSzVyPUGuNFkhdk1?	NE\wUYNUSU6JRWK=
MZ7-mel	NEPXfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXKdlBvUUN3ME2xMlA6KG6P	MlXlV2FPT0WU
D-392MG	NVrxboNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwMTDuUS=>	Mn7pV2FPT0WU
CCRF-CEM	NWfscI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDWTWM2OD1zLkGzJI5O	NHTqbIZUSU6JRWK=
EM-2	NXXGR5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v6PWlEPTB;MT6xOkBvVQ>?	MVnTRW5ITVJ?
HAL-01	NYHwWZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[3TmlEPTB;MT6xPEBvVQ>?	NETMUoxUSU6JRWK=
TE-8	NH32bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PsNmlEPTB;MT6xPUBvVQ>?	Mn3SV2FPT0WU
NCI-H1882	M4rSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTRTWM2OD1zLkKgcm0>	MXHTRW5ITVJ?
Daudi	M13BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rtcmlEPTB;MT6yNkBvVQ>?	MXXTRW5ITVJ?
BL-41	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XMU2lEPTB;MT6yOUBvVQ>?	NYDM[FViW0GQR1XS
SR	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nWcWlEPTB;MT6yOUBvVQ>?	MXHTRW5ITVJ?
KM12	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYr1PWw2UUN3ME2xMlI4KG6P	NEDT[4VUSU6JRWK=
K5	M2TEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnmWFNmUUN3ME2xMlI5KG6P	NHPyZ2ZUSU6JRWK=
A3-KAW	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILkZ4hKSzVyPUGuNlghdk1?	MYPTRW5ITVJ?
CMK	NI\I[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHCVm54UUN3ME2xMlI6KG6P	NIfYSodUSU6JRWK=
Calu-6	M{X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq1dXhtUUN3ME2xMlI6KG6P	MkHPV2FPT0WU
IST-SL2	NXjsXXViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDRb5NKSzVyPUGuN\|Ehdk1?	NYDHOY9pW0GQR1XS
OPM-2	M{XOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rncGlEPTB;MT6zN{BvVQ>?	M2P3UnNCVkeHUh?=
DU-4475	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjBSWZIUUN3ME2xMlM3KG6P	NFf3OmFUSU6JRWK=
ECC12	M4\3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDTXmlMUUN3ME2xMlM4KG6P	M13aUXNCVkeHUh?=
L-540	NUTwbY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TyS2lEPTB;MT6zO{BvVQ>?	MU\TRW5ITVJ?
CAS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XGeWlEPTB;MT6zO{BvVQ>?	M2TiSXNCVkeHUh?=
PF-382	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzFU2ZKSzVyPUGuOFchdk1?	NXvXOYl7W0GQR1XS
LS-411N	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrETWM2OD1zLkWzJI5O	M4i5VXNCVkeHUh?=
NCI-H69	M{XTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\UTWM2OD1zLkW0JI5O	M2rwVXNCVkeHUh?=
NB12	NUDXSpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjBRllpUUN3ME2xMlU3KG6P	NF\CW3JUSU6JRWK=
HEL	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYW0b\|ZGUUN3ME2xMlYyKG6P	MX3TRW5ITVJ?
GCIY	NHPGXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDFRm1yUUN3ME2xMlYzKG6P	NWW1TmhyW0GQR1XS
EHEB	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzBcIZDUUN3ME2xMlY4KG6P	MVLTRW5ITVJ?
TGBC1TKB	NGf1[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXJTWM2OD1zLkexJI5O	NX\rVZJvW0GQR1XS
KURAMOCHI	M2\2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPyTWM2OD1zLkeyJI5O	MlHTV2FPT0WU
U-266	M1LiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTxTWM2OD1zLke2JI5O	NE\xepFUSU6JRWK=
LC4-1	NF;U[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXWOJdKSzVyPUGuO\|khdk1?	MXzTRW5ITVJ?
NCI-H2126	M1XvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLlcmJbUUN3ME2xMlghdk1?	MUnTRW5ITVJ?
NCI-H1092	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:xfm1KSzVyPUGuPEBvVQ>?	MXfTRW5ITVJ?
GB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i1U2lEPTB;MT64NUBvVQ>?	MmXaV2FPT0WU
MV-4-11	NFfPTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\QbJFKSzVyPUGuPFIhdk1?	NIH3[ZBUSU6JRWK=
Becker	M4fWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwOEOgcm0>	NUTTZ4lYW0GQR1XS
MPP-89	M3;vdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwOEmgcm0>	NFXHV\|VUSU6JRWK=
BE-13	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i4TmlEPTB;MT65N{BvVQ>?	NV;s[YRLW0GQR1XS
697	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjjTWM2OD1zLkm5JI5O	M3K0VnNCVkeHUh?=
NKM-1	NUPq[25ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPXTWM2OD1{IH7N	MUPTRW5ITVJ?
NB13	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\neYJKSzVyPUKgcm0>	NX\sWVQ2W0GQR1XS
LS-123	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJwMEKgcm0>	NX3sSGdKW0GQR1XS
NB17	M2HDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\YT4hKSzVyPUKuNFQhdk1?	NFv3PWRUSU6JRWK=
LAN-6	M4\mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mli2TWM2OD1{LkC1JI5O	Mor2V2FPT0WU
EW-24	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjIUlNKSzVyPUKuNFghdk1?	MkXFV2FPT0WU
NOS-1	NVXxcJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XNcmlEPTB;Mj6xNUBvVQ>?	Ml72V2FPT0WU
BL-70	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PXfWlEPTB;Mj6xNkBvVQ>?	Ml3sV2FPT0WU
GT3TKB	NXTpUnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkmwTWM2OD1{LkGyJI5O	MVjTRW5ITVJ?
HH	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r4VGlEPTB;Mj6xN{BvVQ>?	MmfDV2FPT0WU
KE-37	MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJwMUOgcm0>	M4i5S3NCVkeHUh?=
MOLT-4	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIm2bVdKSzVyPUKuNVMhdk1?	NWf5d4QxW0GQR1XS
EKVX	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPQeVBYUUN3ME2yMlE1KG6P	NUHJV2hZW0GQR1XS
KGN	M13jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTJwMUWgcm0>	MYnTRW5ITVJ?
ES4	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHrPHRxUUN3ME2yMlE3KG6P	MoHEV2FPT0WU
SJSA-1	NVPGV5RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3tTWM2OD1{LkKxJI5O	M2f3XHNCVkeHUh?=
KMOE-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rkVWlEPTB;Mj6yN{BvVQ>?	MVzTRW5ITVJ?
NB5	NUXVNFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJwMkegcm0>	M2jFZXNCVkeHUh?=
BC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe5R25KSzVyPUKuN\|Ehdk1?	NXGzVodGW0GQR1XS
NB10	NWXZbphrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzQTWM2OD1{LkOyJI5O	NXrJWZFiW0GQR1XS
RPMI-8226	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu3OJlPUUN3ME2yMlM2KG6P	MX7TRW5ITVJ?
SCC-3	NVjMbWNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDRSmU3UUN3ME2yMlM4KG6P	NVfLb2NRW0GQR1XS
ARH-77	M1HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHO4W\|hKSzVyPUKuN\|ghdk1?	NGS5fJdUSU6JRWK=
NCI-H748	NIjsSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIOwTIFKSzVyPUKuN\|khdk1?	MlXXV2FPT0WU
KU812	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{D5ZWlEPTB;Mj60NkBvVQ>?	NYD4OmxpW0GQR1XS
NCI-H64	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vJdmlEPTB;Mj60OEBvVQ>?	NYPveZhQW0GQR1XS
NB69	M2rQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLHTWM2OD1{LkS2JI5O	NVvE[YpwW0GQR1XS
KNS-81-FD	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJwNEigcm0>	MV3TRW5ITVJ?
LB1047-RCC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXNOHdbUUN3ME2yMlU4KG6P	NV3UeI9vW0GQR1XS
EB-3	NV7xeYVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\qRldKSzVyPUKuOlYhdk1?	M3nQT3NCVkeHUh?=
Mo-T	NIi5SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTQTWM2OD1{Lke0JI5O	MXLTRW5ITVJ?
EW-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW0VZMyUUN3ME2yMlc2KG6P	MXvTRW5ITVJ?
CTV-1	NWm2V5NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4POcWlEPTB;Mj64JI5O	Mm\EV2FPT0WU
ETK-1	NEDiUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHZb4ZbUUN3ME2yMlg1KG6P	NYWwd2k5W0GQR1XS
C2BBe1	Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jWRWlEPTB;Mj64PUBvVQ>?	Mnf4V2FPT0WU
MOLT-16	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:ydHpKSzVyPUKuPFkhdk1?	NGfRRYJUSU6JRWK=
SW954	NFHtNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33iV2lEPTB;Mj65JI5O	NH3neJlUSU6JRWK=
HT	M4XTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NISyZ\|JKSzVyPUOuNFIhdk1?	MorNV2FPT0WU
KARPAS-299	M1W4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PQOGlEPTB;Mz6wOkBvVQ>?	MYrTRW5ITVJ?
MONO-MAC-6	NIfLN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNwMTDuUS=>	NFKwOYFUSU6JRWK=
CGTH-W-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELX[2FKSzVyPUOuNUBvVQ>?	NELDPFJUSU6JRWK=
SK-PN-DW	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fZ[mlEPTB;Mz6xOEBvVQ>?	NVfS[VZiW0GQR1XS
CW-2	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXXd3BKSzVyPUOuNlEhdk1?	MkDPV2FPT0WU
SK-N-DZ	NFrSS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO5fJFKSzVyPUOuNlYhdk1?	MXnTRW5ITVJ?
NEC8	M{WyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jhT2lEPTB;Mz6zOUBvVQ>?	M33wb3NCVkeHUh?=
LB996-RCC	MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTNwNDDuUS=>	NITmWW9USU6JRWK=
DB	NFLOdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFH1S5JKSzVyPUOuOFEhdk1?	M4W4RXNCVkeHUh?=
TE-15	M1H0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4f0OmlEPTB;Mz60N{BvVQ>?	M2q0dXNCVkeHUh?=
COR-L88	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHuTFU6UUN3ME2zMlQ4KG6P	NWO2O2M2W0GQR1XS
LAMA-84	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXKy[FVwUUN3ME2zMlQ6KG6P	M4\vNnNCVkeHUh?=
MEG-01	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDsTWM2OD1\|LkS5JI5O	M3;aO3NCVkeHUh?=
LOXIMVI	M4L6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LvcmlEPTB;Mz61JI5O	NYnvenJkW0GQR1XS
RPMI-8402	NFm0O4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4K3dWlEPTB;Mz61JI5O	M3X4VXNCVkeHUh?=
KARPAS-45	NUjUUZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf5TWM2OD1\|LkW0JI5O	NFzvfZpUSU6JRWK=
HCC1187	NXy2PVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPGTWM2OD1\|LkW0JI5O	MVPTRW5ITVJ?
MZ1-PC	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{H4bmlEPTB;Mz61OEBvVQ>?	MkD5V2FPT0WU
no-11	NXTBVok4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\uW3RXUUN3ME2zMlU2KG6P	M2nxO3NCVkeHUh?=
EVSA-T	NE\0NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvXZmd5UUN3ME2zMlYhdk1?	M1:4enNCVkeHUh?=
DJM-1	M2\3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLZOpRqUUN3ME2zMlY{KG6P	M4HQ[nNCVkeHUh?=
COLO-684	NIrjcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M331dGlEPTB;Mz62OkBvVQ>?	MVnTRW5ITVJ?
NMC-G1	M13BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHhXGNKSzVyPUOuOlghdk1?	M4LaPXNCVkeHUh?=
LC-1F	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjQTGxKSzVyPUOuO\|Qhdk1?	NWLhb297W0GQR1XS
RL95-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfRUG1mUUN3ME2zMlc6KG6P	MX;TRW5ITVJ?
COLO-320-HSR	M2nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELOVmpKSzVyPUOuPVIhdk1?	MWDTRW5ITVJ?
RCC10RGB	NFfPeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYS4NWNkUUN3ME2zMlk{KG6P	NFLvRZpUSU6JRWK=
HD-MY-Z	NUTnUmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml24TWM2OD1\|LkmzJI5O	MVPTRW5ITVJ?
NCI-H2141	NXzSW4piT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDLTWM2OD12LkC1JI5O	NUDhN2sxW0GQR1XS
K-562	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzQTWM2OD12LkGyJI5O	NVXldlVCW0GQR1XS
NCI-H1648	NYjtbIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjjcWJKSzVyPUSuNVMhdk1?	MVHTRW5ITVJ?
OMC-1	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTRwMUigcm0>	NVjs[VY6W0GQR1XS
LB647-SCLC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnITWM2OD12LkKyJI5O	M3T3W3NCVkeHUh?=
TE-12	NGmxXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfEUplTUUN3ME20MlI2KG6P	NH7pXnJUSU6JRWK=
NOMO-1	NWrDcodNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDsR25KUUN3ME20MlM{KG6P	MlTDV2FPT0WU
Raji	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfETWM2OD12LkS2JI5O	M3m3THNCVkeHUh?=
NALM-6	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTRwNEmgcm0>	NHjHfFVUSU6JRWK=
HL-60	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnNTWM2OD12Lk[3JI5O	NU\Vd2NPW0GQR1XS
IST-SL1	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlO0TWM2OD12Lk[4JI5O	NY\qTlBJW0GQR1XS
MHH-PREB-1	M164V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7VOHczUUN3ME20Mlg3KG6P	M2S3[HNCVkeHUh?=
MHH-NB-11	M3zDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\ZTWM2OD12LkmxJI5O	MYXTRW5ITVJ?
JiyoyeP-2003	NXq1VZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTVibl2=	NH\NZ2ZUSU6JRWK=
SBC-1	NXrGfGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvtfHZKSzVyPUWuNFEhdk1?	NXPPZoV1W0GQR1XS
CHP-126	MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLDTWM2OD13LkC2JI5O	MnvQV2FPT0WU
LU-139	NV74cWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELQVXNKSzVyPUWuNVMhdk1?	NFLyNXJUSU6JRWK=
NCI-SNU-5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3L3WWlEPTB;NT6xO{BvVQ>?	M4D0PXNCVkeHUh?=
SW962	M{PUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmD3TWM2OD13LkKxJI5O	NGf1T4JUSU6JRWK=
EW-1	M3jEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXnNmlvUUN3ME21MlMyKG6P	MlrTV2FPT0WU
NCI-H1417	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTVwNUGgcm0>	M3TRRXNCVkeHUh?=
LU-65	NXfHdGFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHSwSmNKSzVyPUWuPFQhdk1?	NFyweJFUSU6JRWK=
D-502MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXldHNNUUN3ME22MlM4KG6P	NEPFSmlUSU6JRWK=
BC-3	NILybXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYS0TmRSUUN3ME22MlYyKG6P	MnHRV2FPT0WU
GDM-1	M{eyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfXTWM2OD14Lke3JI5O	NFP6fldUSU6JRWK=
NCI-H2196	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTZwODDuUS=>	MljmV2FPT0WU
NB1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;scHRKSzVyPU[uPFghdk1?	MkWzV2FPT0WU
NCI-H345	NH22dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnGfnVKSzVyPUeuNkBvVQ>?	MlvYV2FPT0WU
SU-DHL-1	NFfhXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWK0foFOUUN3ME23MlI1KG6P	M2ThWXNCVkeHUh?=
JVM-2	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTdwMkigcm0>	MoLyV2FPT0WU
LU-134-A	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fSNmlEPTB;Nz6zPUBvVQ>?	Mn7IV2FPT0WU
NCI-H1694	NHLIPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjuRlN7UUN3ME23MlU5KG6P	MnXaV2FPT0WU
NCI-SNU-16	M3:2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTdwNkWgcm0>	M1LHeHNCVkeHUh?=
L-363	NXnl[XF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTCTWM2OD15Lkegcm0>	MnX3V2FPT0WU
KG-1	NXjJVXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjxdm1KSzVyPUeuPVQhdk1?	NX3HR3pWW0GQR1XS
MN-60	M3Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEiyTZhKSzVyPUiuNVQhdk1?	NIK4eVJUSU6JRWK=
NB6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRThwNEigcm0>	MVjTRW5ITVJ?
MLMA	M3XSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITreFNKSzVyPUiuPFUhdk1?	Ml;5V2FPT0WU
ATN-1	M{HN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTXW4tKSzVyPUiuPFkhdk1?	M1TqSHNCVkeHUh?=
SK-NEP-1	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1G5b2lEPTB;OT6wNUBvVQ>?	MmrlV2FPT0WU
DMS-114	M1\kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT2[mtKSzVyPUmuOlIhdk1?	MXLTRW5ITVJ?
CTB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG5PI9KSzVyPUmuOlchdk1?	M4nv[nNCVkeHUh?=
NCI-H2081	NYLE[nJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTFyLkC5JI5O	MnHkV2FPT0WU
ES5	NXTNbJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDpS5NKSzVyPUGwMlM5KG6P	NX65Tm04W0GQR1XS
HCC1599	NFO1T\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFzLkmxJI5O	M3fB[3NCVkeHUh?=
NCI-H23	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[1TWM2OD1zMj6xNkBvVQ>?	MojXV2FPT0WU
NCI-H1581	NFfFcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTF{LkK4JI5O	NGPTelhUSU6JRWK=
JVM-3	NILDOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfBe\|JKSzVyPUGyMlk6KG6P	NETFb2RUSU6JRWK=
NCI-SNU-1	M{fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF\|LkG5JI5O	M2rXXHNCVkeHUh?=
NB7	NF;GO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljiTWM2OD1zNT65NkBvVQ>?	M1fJV3NCVkeHUh?=
JAR	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DUfWlEPTB;MU[uNVMhdk1?	MlnuV2FPT0WU
TGW	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zlRmlEPTB;MU[uOFghdk1?	NFXGT49USU6JRWK=
U-87-MG	M331fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\MTWM2OD1zNj63OkBvVQ>?	M3j0TXNCVkeHUh?=
NCI-H1436	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonHTWM2OD1zNz6wNUBvVQ>?	M2HEfHNCVkeHUh?=
GOTO	NUjidotDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfKPVVKSzVyPUG3MlA3KG6P	Mm\MV2FPT0WU
COLO-800	NYDwOZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P4[mlEPTB;MUeuOlQhdk1?	NWrQPGpMW0GQR1XS
MFM-223	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF5LkmxJI5O	MoW2V2FPT0WU
EW-18	NXjYTmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVL4Z2JEUUN3ME2xO{46PiCwTR?=	M4DkVXNCVkeHUh?=
NB14	NWfiS2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zP[2lEPTB;MUeuPVghdk1?	NIPWdFhUSU6JRWK=
EB2	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTF6LkC4JI5O	MmOxV2FPT0WU
EoL-1-	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPRTWM2OD1zOD6zNUBvVQ>?	M2n5ZnNCVkeHUh?=
NCCIT	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlf0TWM2OD1zOD6zOkBvVQ>?	NFjqN4VUSU6JRWK=
DG-75	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF6Lk[xJI5O	M1zuR3NCVkeHUh?=
HCC2218	NIDUR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF7LkWgcm0>	NW\ofJY{W0GQR1XS
TE-6	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvGTWM2OD1{MD6wPEBvVQ>?	NWnRO5YzW0GQR1XS
SF539	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHJTWM2OD1{MD62O{BvVQ>?	NWXXZ\|VSW0GQR1XS
NCI-H446	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJzLkG4JI5O	M1j4T3NCVkeHUh?=
IST-MES1	NIH5OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7wUJg4UUN3ME2yNk44PyCwTR?=	M4HDO3NCVkeHUh?=
NCI-H82	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ\|LkCyJI5O	NVX5V2J3W0GQR1XS
HCC2157	NH3nd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJ\|LkGzJI5O	NF71UWlUSU6JRWK=
EW-12	M4[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnNVG04UUN3ME2yN{4yPyCwTR?=	NF21SFBUSU6JRWK=
SIMA	NULJbZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnrWWpXUUN3ME2yN{4{QCCwTR?=	Mm\rV2FPT0WU
DOHH-2	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1npT2lEPTB;MkOuOFUhdk1?	MnfpV2FPT0WU
IM-9	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLGbmRxUUN3ME2yN{42PCCwTR?=	M4LlWXNCVkeHUh?=
EC-GI-10	M1HRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfjfXhtUUN3ME2yOE4zOyCwTR?=	NI\YXGtUSU6JRWK=
HDLM-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvYeFRKSzVyPUK0MlU1KG6P	MWLTRW5ITVJ?
LS-1034	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{L0VmlEPTB;MkWuO\|Uhdk1?	NUDsUVN3W0GQR1XS
REH	NV3lb3duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PNN2lEPTB;Mk[uOFEhdk1?	MknNV2FPT0WU
LU-165	NX:3fWNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTJ4LkeyJI5O	MWrTRW5ITVJ?
NH-12	M1zmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TEZmlEPTB;MkeuOlchdk1?	M2OzVHNCVkeHUh?=
WSU-NHL	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI[z[oZKSzVyPUK4MlM6KG6P	NGnnNFhUSU6JRWK=
ECC4	NGi5NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\3W4JKSzVyPUK4Mlc6KG6P	M4n6cnNCVkeHUh?=
OCI-AML2	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXIOJBKSzVyPUK5MlY6KG6P	NGruSpdUSU6JRWK=
EW-3	M3rBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\STpdKSzVyPUOwMlU6KG6P	M17LNHNCVkeHUh?=
NCI-H526	NFG0fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTN{LkW0JI5O	NFvGPIVUSU6JRWK=
NCI-H719	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\1eWlEPTB;M{SuN\|Ehdk1?	M4LMXHNCVkeHUh?=
KARPAS-422	NInkNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXWeVlKSzVyPUO1MlA1KG6P	NFq1WmFUSU6JRWK=
SK-MEL-1	M3\4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTN3LkG3JI5O	NHrocJJUSU6JRWK=
ES3	NXi1VFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHQTYxbUUN3ME2zOU4yQSCwTR?=	MYLTRW5ITVJ?
UACC-812	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[2TWM2OD1\|NT60OEBvVQ>?	NYL5ToF1W0GQR1XS
C8166	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TOSWlEPTB;M{WuO{BvVQ>?	NUHhUIl6W0GQR1XS
MDA-MB-134-VI	M1fIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTN3Lki3JI5O	NV;vTnZyW0GQR1XS
D-283MED	M4LNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jI[mlEPTB;M{euO\|khdk1?	NVfJVHZ{W0GQR1XS
SHP-77	NUfZ[XI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTN6LkCzJI5O	MYDTRW5ITVJ?
NCI-H2227	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv3OVZKSzVyPUSwMlQ6KG6P	NYn4dYZLW0GQR1XS
SKM-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;BOXBKSzVyPUSyMlY{KG6P	NFXn[HhUSU6JRWK=
L-428	NEjjU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTR\|Lki2JI5O	Mn35V2FPT0WU
RPMI-6666	NG\1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPrTWM2OD12NT64PUBvVQ>?	NF3QbWNUSU6JRWK=
NCI-H716	NYXGRnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTLWFVmUUN3ME20PE45OSCwTR?=	MXjTRW5ITVJ?
DMS-79	NUW2V5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPDUZFKSzVyPUWwMlcyKG6P	NHTIfWVUSU6JRWK=
RS4-11	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWP3ephmUUN3ME21NE45QCCwTR?=	M17ubXNCVkeHUh?=
NCI-H720	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XvTWlEPTB;NUGuNVEhdk1?	MnyzV2FPT0WU
MC-CAR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j2TGlEPTB;NUGuOVIhdk1?	NVizXI5vW0GQR1XS
TALL-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\N[JhMUUN3ME21N{46OSCwTR?=	NUXnS3pIW0GQR1XS
NCI-N87	NHnXdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3myWGlEPTB;NUSuNVghdk1?	NVzxPIlNW0GQR1XS
P30-OHK	M2LhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{OxbWlEPTB;NUSuOlEhdk1?	MlrKV2FPT0WU
LP-1	NFn0TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\0fplDUUN3ME22NU4zQCCwTR?=	Ml\1V2FPT0WU
YT	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrKTWM2OD14MT64JI5O	NGSzZ5NUSU6JRWK=
MRK-nu-1	NVyxXWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf6TmpKSzVyPU[xMlgzKG6P	MVrTRW5ITVJ?
BT-474	NWXZeJVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXzWYdKSzVyPU[1JI5O	MXHTRW5ITVJ?
NCI-H322M	NIr6fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTZ4LkGxJI5O	NIXoPXZUSU6JRWK=
NCI-H128	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\OXpVEUUN3ME23OE44PyCwTR?=	NIO2bpdUSU6JRWK=
KMS-12-PE	NVLoNnFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fQSmlEPTB;N{[uNlQhdk1?	MXrTRW5ITVJ?
KP-N-YS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnzTWM2OD15Nj63OEBvVQ>?	M1z1c3NCVkeHUh?=
ALL-PO	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi3dmRKSzVyPUe3MlY3KG6P	NEPQSmpUSU6JRWK=
EW-13	NW\LeVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTd5Lke2JI5O	NIL2TIlUSU6JRWK=
EW-11	NEO1UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTd6LkWyJI5O	M2HYSHNCVkeHUh?=
SK-N-FI	NFnGepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[wWmlEPTB;OECuNkBvVQ>?	NUTwRoF1W0GQR1XS
CAL-148	NUPkdHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITJR5BKSzVyPUixMlg1KG6P	MofZV2FPT0WU
RL	NHX5eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULtTYlFUUN3ME24Ok4xQSCwTR?=	MYnTRW5ITVJ?
AM-38	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE[2NWZKSzVyPUi4MlA5KG6P	Ml3VV2FPT0WU
RH-1	M{XRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfXVmxKSzVyPUm5Mlg2KG6P	MnXLV2FPT0WU
NCI-H1770	NXu1Rph6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXWUlFKSzVyPUGwNk41QSCwTR?=	MU\TRW5ITVJ?
SIG-M5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFyNT6wOkBvVQ>?	NVXhemdiW0GQR1XS
GR-ST	NInvbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjIb3JKSzVyPUGxN{4{PCCwTR?=	NF6xSoNUSU6JRWK=
ST486	M37B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFzND6wOkBvVQ>?	M1zwSnNCVkeHUh?=
NCI-H1650	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml:4TWM2OD1zMUWuNlkhdk1?	NUnHOmpiW0GQR1XS
MHH-CALL-2	NWXtW3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfHV4hKSzVyPUGxOU44KG6P	MYDTRW5ITVJ?
BV-173	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v6bWlEPTB;MUKyMlcyKG6P	MY\TRW5ITVJ?
MC116	NGS5RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1L4VGlEPTB;MUS4Mlg2KG6P	M3Ppe3NCVkeHUh?=
NCI-H524	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jPTWlEPTB;MUW5MlEhdk1?	MlLWV2FPT0WU
SCLC-21H	M33MdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS4T3NKSzVyPUG1PU41OSCwTR?=	M1HzVnNCVkeHUh?=
NCI-H1304	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrMc4FCUUN3ME2xOlkvOjFibl2=	MnPJV2FPT0WU
NCI-H510A	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjmRVBKSzVyPUG4OU4{PyCwTR?=	NHLrUYlUSU6JRWK=
NCI-H209	NFzmSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nJfGlEPTB;MUm2MlUzKG6P	MUPTRW5ITVJ?
KM-H2	NEXmW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfhNJFKSzVyPUG5O{4xPSCwTR?=	NVvHZYZCW0GQR1XS
NCI-H1395	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\mTWM2OD1{MUCuNVMhdk1?	MlXqV2FPT0WU
NCI-H1155	M2HUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ\|MD6zNkBvVQ>?	MXTTRW5ITVJ?
COR-L279	NWf6[VVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ3Mj6xO{BvVQ>?	Mn2xV2FPT0WU
NCI-H1299	NF7y[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnnOZo4UUN3ME2yOlEvPzFibl2=	M3T6TXNCVkeHUh?=
EW-22	NWrDSXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIex[4lKSzVyPUK2N{44PSCwTR?=	MnTZV2FPT0WU
SK-MEL-2	NHOyPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[0TWM2OD1{OEGuPUBvVQ>?	M1jYNHNCVkeHUh?=
KASUMI-1	MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:wT2lEPTB;MkizMlA2KG6P	NHfJN4hUSU6JRWK=
NCI-H187	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHrcnNGUUN3ME2yPFcvODhibl2=	M1L5OHNCVkeHUh?=
NCI-H2171	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1mwV2lEPTB;Mki4MlkzKG6P	Mkm4V2FPT0WU
LNCaP-Clone-FGC	NH:2cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ7NT6yOkBvVQ>?	MoK0V2FPT0WU
NCI-H1522	NIj1U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrDXHFoUUN3ME2zNFcvODVibl2=	NGLQW3RUSU6JRWK=
SCH	NF7oZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHxWlBKSzVyPUOyNk4zOiCwTR?=	NVj4Uop{W0GQR1XS
THP-1	M1naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlGwTWM2OD1\|MkKuOkBvVQ>?	NUHYbJlNW0GQR1XS
SNU-C1	NH;l[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTN4Mj6wPUBvVQ>?	M3;RcnNCVkeHUh?=
CA46	M2\C[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzOTWM2OD1\|N{OuOlMhdk1?	M{nKZ3NCVkeHUh?=
NCI-H1963	M4LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTN6Nj6xPUBvVQ>?	M{TSO3NCVkeHUh?=
DEL	NH3SWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\yZldKSzVyPUO5NU4zPyCwTR?=	M3jyc3NCVkeHUh?=
TUR	M4DQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfmUYNvUUN3ME2zPVYvPjFibl2=	NFWxfo9USU6JRWK=
NCI-H226	NHGxcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTRyMz6yN{BvVQ>?	NYLQRoJpW0GQR1XS
COLO-668	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjwTWM2OD12MEOuOVchdk1?	NXewXVhMW0GQR1XS
CPC-N	NGnRNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTRyMz63O{BvVQ>?	M{D0SHNCVkeHUh?=
NCI-H889	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrDTGdKSzVyPUS2NU46OiCwTR?=	Mn;DV2FPT0WU
J-RT3-T3-5	NV\nfppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTV\|Mj61O{BvVQ>?	M362eHNCVkeHUh?=
MSTO-211H	NIrsTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPuTWM2OD13N{SuNlYhdk1?	MVfTRW5ITVJ?
SCC-15	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPKTWM2OD14NkeuOFchdk1?	MnGwV2FPT0WU
SUP-T1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnO2TWM2OD14OE[uNFQhdk1?	NV3pdHZ2W0GQR1XS
DMS-153	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf1VG5KSzVyPUe0Ok45OyCwTR?=	NIDyc3dUSU6JRWK=
MS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT5TWM2OD15NUmuOFIhdk1?	MoG3V2FPT0WU
TC-YIK	NWPrOZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\BUGlEPTB;N{ixMlAyKG6P	NYmxSGFPW0GQR1XS
RPMI-8866	M4f4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFyME[uNlgh\|ryP	NVjCSVREW0GQR1XS
KY821	NEXLPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHjU5RVUUN3ME2xNFM3NjB2IN88US=>	MWjTRW5ITVJ?
P31-FUJ	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPzTWM2OD1zMUGyMlc2KM7:TR?=	M{jpeHNCVkeHUh?=
COLO-824	NFr0VWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjpd45TUUN3ME2xNlYyNjd6IN88US=>	MmDDV2FPT0WU
U-698-M	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfqdWZ1UUN3ME2yNlYzNjF3IN88US=>	NVrXUmVjW0GQR1XS
TE-441-T	NWjQeoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXzN\|BKSzVyPUK1NlEvPyEQvF2=	MVfTRW5ITVJ?
IMR-5	NVnyOZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrOTWM2OD1\|NEC5MlYzKM7:TR?=	NGLWbFRUSU6JRWK=
NCI-H1838	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTRzOE[uN\|Ih\|ryP	NXPT[W1QW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

体内試験

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[4]	+ 展開 Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験： ^[5]	+ 展開細胞株： Human multiple myeloma cells line U266 濃度： ~10 μM 反応時間： 2 days 実験の流れ： The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (参考用のみ)
動物試験： ^[3]	+ 展開動物モデル： Human plasmacytoma xenografts RPMI 8226 製剤： Saline 投薬量： 1 mg/kg 投与方法： i.v. twice weekly for 4 weeks, then once weekly (参考用のみ)

参考

+ 展開

溶解度 (25°C)

体外	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+30% PEG 300+ddH2O 混合させたのち直ちに使用することを推奨します。	5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Bortezomib (PS-341) SDFをダウンロードする

分子量	384.24
化学式	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
保管	3年 -20°C 粉
保管	2年 -80°C in solvent
別名	LDP-341, MLM341

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829020	Not yet recruiting	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	Mayo Clinic\|National Cancer Institute (NCI)	March 1 2019	Phase 1
NCT03617484	Recruiting	Mantle Cell Lymphoma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03617484	Recruiting	Mantle Cell Lymphoma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03829020	Not yet recruiting	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	Mayo Clinic\|National Cancer Institute (NCI)	March 1 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
回答：
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

相関Proteasome製品

VR23

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.
Marimastat (BB-2516)

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Ixazomib (MLN2238)

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
Ixazomib (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

研究分野別

製品類型

Bortezomib (PS-341)

文献中Selleckの製品使用例(250)

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Bortezomib (PS-341) SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技術サポート

よくある質問（FAQ）

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品